Background: Intermittent treatment could improve the convenience, tolerability and cost of ART, as well as patients' quality of life. We conducted a 48 week multicentre study of a 4-days-a-week antiretroviral regimen in adults with controlled HIV-1-RNA plasma viral load (VL).
Introduction
The treatment goal in HIV infection is to achieve continuous viral suppression, which has been shown to reduce morbidity and mortality and to reduce the risk of viral transmission. Current guidelines on combined ART (cART) recommend the use of two nucleoside analogues and a third agent chosen from the following classes: NNRTI, boosted PI and integrase strand transfer inhibitors (INSTIs).
1,2 cART achieves complete viral suppression in most patients, 3 but treatment has to be continued lifelong, with a risk of poor adherence, viral escape and long-term toxicity, particularly in ageing patients with comorbidities. Moreover, with growing economic constraints and increasing numbers of patients on therapy, the use of antiretroviral combinations with lower cost becomes essential.
Several attempts have been made to lower drug exposure during maintenance therapy, including dose reductions, 4, 5 dual-agent combinations 6 and boosted PI monotherapy. 7 Although feasible in patients with fully suppressed viral load (VL), these strategies are not applicable to all patients and might be associated with lowlevel viral escape. 7 After Dybul et al., 8 several teams tested short-cycle structured intermittent maintenance therapy, mostly with a 5 days on/2 days off efavirenz-based regimen, as in the BREATHER randomized trial. 9, 10 We have previously observed no virological failures in a cohort of 98 patients treated for 1 year with a 4 days on/3 days off maintenance regimen. 11 Here we report the results of a multicentre pilot study (ANRS 162-4D) designed as a proof-of concept study to assess the efficacy and tolerability of a 4 days on/3 days off maintenance regimen in patients already on effective standard antiretroviral regimens. On this maintenance regimen with potential reduced long-term exposure to antiretroviral drugs, we also assessed the evolution of the viral reservoir, the inflammatory markers and the modification of plasma drug concentrations.
Methods

Study design and participants
ANRS 162-4D was a 48 week, single-arm, prospective multicentre trial, conducted between July 2014 and January 2016. Patients were eligible if they were 18 years; had confirmed HIV-1 infection; had been receiving cART for .12 months, based on two nucleoside/tide analogues (tenofovir disoproxil fumarate, abacavir, lamivudine or emtricitabine) and a third agent consisting of a boosted PI (darunavir, lopinavir or atazanavir) or NNRTI (efavirenz, rilpivirine or etravirine), all given at standard recommended dosages, with no change in regimen in the previous 4 months; had VL 50 RNA copies/mL for at least 1 year; had a CD4 cell count .250 cells/mm 3 ]; a negative pregnancy test at screening and agreed to use contraception during the study for women of childbearing age; and provided written informed consent.
Ethics
The trial was conducted in accordance with Good Clinical Practices and the ethical principles of the Helsinki Declaration and followed ANRS recommendations for clinical research. The Ile-de-France XI Ethics Review Committee approved the study on 13 February 2014 and all the participants gave their written informed consent before entering the study. The study was registered with ClinicalTrials.gov (NCT02157311) and EudraCT (2014-000146-29).
Procedures
The screening visit [week 4 (W4)] was designed to obtain informed consent and to check the inclusion criteria. The RNA sequence of any previous drug resistance genotype was collected and analysed (ANRS-AC11 resistance algorithm, v. 0.24-2014, http://www.frenchresistance.org/). Four weeks later, inclusion in the study was confirmed and short-cycle maintenance therapy was started at the day 0 (D0) visit. The patients chose three consecutive days off therapy (Friday-Sunday or Saturday-Monday) and continued this 4/7 strategy until the end of the study. They were assessed clinically and biologically every 4 weeks from D0 to W16, then every 8 weeks until W48. A last blood sample was taken at W51 to confirm the final end point result. Laboratory tests were scheduled at the end of the 3 day offtreatment period, except at W16 and W40 (on treatment).
Laboratory tests
VL (Roche Cobas TaqMan HIV-1 v. 1.2 or Abbott Real-Time HIV-1) and T cell subpopulations were measured at every visit in the local laboratories. VL values .50 copies/mL were confirmed on a new sample taken 2-4 weeks later and events were classified as virological failure if VL at control was .50 copies/mL and as viral blip otherwise. An additional plasma sample was obtained and frozen at each visit for VL assay, drug resistance genotyping and drug assays. Whole-blood samples for centralized total cellassociated DNA measurement (real-time PCR, Biocentric, Bandol, France) and serum samples for inflammatory marker assays 
Pharmacological evaluation
The residual plasma concentrations of the third agent (PI or NNRTI) used in the antiretroviral combination were determined on treatment at D0, W16 and W40, and off treatment (D3) at W4, W8, W12, W24, W32 and W48, using a validated turbulent flow chromatographic method with triple quadrupole MS detection and electrospray ionization interface (Thermo Fisher, Les Ulis, France). The results were interpreted according to quantification and efficacy thresholds (respectively, in ng/mL, 100 and 1000 for efavirenz, 10 and 50 for etravirine, 5 and 40 for rilpivirine, 20 and 2000 for darunavir, 20 and 200 for atazanavir, and 20 and 4000 for lopinavir).
12 Tolerability, quality of life and adherence Clinical and biological tolerability was evaluated at each visit. Lipodystrophy (waist and hip size, waist/hip ratio) and metabolic changes (fasting glucose, total cholesterol, HDL cholesterol, LDL cholesterol and triglycerides) were assessed at D0, W24 and W48. Adherence to the study strategy was assessed with a self-administered questionnaire based on last-week recall at each visit and by plasma drug measurements on and off treatment. In addition, a Medication Event Monitoring System (MEMS) capped-container substudy was conducted in a subgroup of participants treated with drugs contained in bottles with compatible caps (Truvada V R , Atripla V R , Eviplera V R , Viread V R ) in five of the centres. Satisfaction with the strategy and quality of life, assessed with the PROQOL-HIV questionnaire 13 and a questionnaire of perceived symptoms, was assessed at D0, W24 and W48.
Outcomes
The primary endpoint was therapeutic success, defined by the absence of virological failure and strategy failure up to W48. Virological failure was defined as a first VL .50 copies/mL, confirmed on a second sample 2-4 weeks later. Strategy failure was defined as discontinuation of the HIV short-cycle maintenance therapy JAC 4/7 strategy for 30 days or more, because of adverse events, the patient's or investigator's decision, or loss to follow-up (absence at more than two consecutive visits). Switches to a drug of the same class were not considered as failure and neither was interruption of the 4/7 strategy for pregnancy.
Secondary outcomes included the proportion of patients with viral blips, the proportion of patients without any signal of viral replication (subgroup of patients tested with Roche-Taqman VL); the occurrence of grade 3/4 adverse events; changes in plasma creatinine, estimated glomerular filtration rate (eGFR) calculated with the MDRD equation, metabolic parameters and hepatic transaminases from D0 to W48; the occurrence of genotypic resistance in case of failure; changes in the CD4 and CD8 cell counts and the CD4/CD8 ratio from D0 to W48, changes in total HIV-DNA in PBMC from D0 to W24 and W48; changes in inflammatory markers from D0 to W48; the dynamics of residual NNRTI or PI concentrations during the on-and offtreatment phases; adherence to the study strategy; and changes in quality of life from D0 to W48.
To assess adherence to the study strategy, we assessed the number of days that the MEMS-cap was opened, divided by number of days that the MEMS-cap was in use during the trial; 9 the number of weeks that the MEMScap was opened exactly 4 days a week, or more or less than 4 days a week; the observance rate, estimated as the number of pills consumed (recorded using the self-reported questionnaire) divided by the number of pills that should theoretically have been consumed, classified as low (,80%), medium (80%-95%), high (95%-100%) or higher than expected (.100%); and changes in drug concentrations between the average of values recorded during the on-treatment period (last intake ,48 h previously) and during the off-treatment period (last intake 48 h previously).
Statistical considerations
The study was designed to detect the difference between the null hypothesis proportion of 80% and the alternative proportion of 90% (an expected success rate) with a type 1 error of 5% and a power of 85%. An estimated 95 patients were required to achieve these goals. Enrolment of 95 patients, increased to 100 patients to account for non-evaluable patients, was requested to achieve these goals.
The primary efficacy endpoint was analysed with an ITT approach. The 95% CI of the observed proportion of patients reaching the efficacy endpoint was calculated with the Kaplan-Meier method.
Variables were summarized as proportions for categorical variables, median and IQR for continuous baseline variables and mean and SD for continuous variables used as endpoints. Changes in continuous variables between baseline and W48 were compared using the Wilcoxon paired test, except for quality-of-life (see below). All continuous variables used as endpoints were analysed with an ITT approach, with the last observation carried forward.
The PROQOL-HIV questionnaire includes eight dimensions with scores ranging from 0 to 100. 13 To assess quality of life and perceived symptoms, we created 10 datasets in which missing data were imputed from each participant's other covariables. In these imputations, missing values were randomly sampled from their predicted distributions.
14 Changes in quality of life dimensions were compared using Student's t-test. Analyses were run on each of the 10 datasets, including the imputed values, and the results were combined with Rubin's rules. 14 Changes in satisfaction with care were estimated with a five-point scale item of the questionnaire, using the generalized estimating equation (GEE) model with a multinomial distribution.
All reported P values are two-tailed, with significance set at 0.05. All analyses were done with SAS version 9.4 for Windows.
Results
Patient characteristics
Between July and October 2014, 119 patients were screened and 103 patients from 17 sites were enrolled in the study (Figure 1 ). Three patients did not initiate the short-cycle strategy and 100 patients were included: 79 patients chose Friday-Sunday as the off period and the other 21 patients chose Saturday-Monday. No patients were lost to follow-up. One patient resumed a 7/7 strategy because of pregnancy.
The patients' baseline characteristics are shown in Table 1 . The median prior duration of viral suppression was 4.0 (2.3-6.4) years. ART consisted of two nucleoside analogues (tenofovir disoproxil fumarate ! emtricitabine, 89 patients; abacavir ! lamivudine, 10 patients; tenofovir disoproxil fumarate ! abacavir, 1 patient), plus either an NNRTI (71 patients) or a boosted PI (29 patients).
Treatment outcomes
The overall success rate at W48 was 96% (95% CI 90%-98%) ( Figure 2 ). Virological failure occurred in three cases, at W4 (VL: 271 copies/mL, confirmed at 785 copies/mL; PI-based therapy), W12 (VL: 124 and 55 copies/mL; NNRTI-based therapy) and W40 (VL: 969 and 227 copies/mL; PI-based therapy) ( Table 2 ). These three patients resumed 7/7 treatment with the same drug combinations, leading to virological suppression. No genotypic resistance de Truchis et al.
mutations were detected at the time of failure. Another patient decided to resume continuous therapy at W4 and was therefore considered as a therapeutic failure.
Four viral blips were observed in three patients, at W4 and W8 (rilpivirine-based therapy, VL 77 and 51 copies/mL, each point controlled with a subsequent VL measure ,50 copies/mL), W24 (rilpivirine-based therapy, VL 182 copies/mL with control ,50 copies/mL) and W48 (boosted atazanavir-based therapy, VL 142 copies/mL with control ,50 copies/mL). In the substudy of 62 patients analysed with Roche Cobas Taqman HIV-1 2.0 assay, the proportions of patients with no signal of replication at D0, W12, W24 and W48 were respectively 71%, 69%, 77% and 70%, with no significant change over time (McNemar test, P . 0.513).
No patient had the baseline ART switched throughout the trial. No HIV-related events occurred during the study. Seven severe adverse events were reported [trauma after sport (2), programmed surgery (2), cutaneous abscess, epileptic crisis, transient neutropenia], none being considered related to the study strategy. There was no statistically significant change in the total number of perceived symptoms recorded with the self-administered questionnaire (data not shown).
Biological outcomes
Changes in the main biological parameters between D0 and W48 are shown in Table 3 . A significant increase in the CD4 cell count (!39+168 cells/mm 3 , P " 0.023) and in the CD4/CD8 ratio (!0.04+0.21, P " 0.034) was observed from D0 to W48. No significant changes in eGFR or lipid values were noted.
Total HIV-1 DNA in PBMC was stable between D0 (2.4+0.7 log 10 copies/10 6 PBMC) and W48 (2.4+0.7 log 10 copies/10 6 PBMC). No significant increase in markers of immune activation was observed (IP-10, IL-6, MIG-1 and CRP), but the CD14s level fell significantly (-200+759 ng/mL, P " 0.001).
Pharmacological data and adherence to therapy
In total, 877 plasma samples were analysed for antiretroviral drug plasma concentrations (292 on treatment and 585 off treatment). All on-treatment concentrations were within the range of efficacy.
Residual off-treatment concentrations were significantly lower (#47% to #99% depending on class and drug used) than ontreatment concentrations (Table 4) , as would be expected with good adherence to the strategy. No significant modification of the HIV short-cycle maintenance therapy JAC concurrent medications taken by the participants was reported, so the changes in drug concentrations both on and off treatment cannot be explained by variation in drug-drug interactions. Self-reported adherence was high (95%-100% of doses taken) in .90% of patients (90.4%-98.8%) at each visit from D0 to W48. The proportion of patients who reported having taken ,80% of their treatment in the previous week was between 1.1% and 7.5% at each visit. The proportion of patients who reported taking their treatment for .4 days in the previous week ranged from 0% to 4.4% at each visit (Figure 3a) .
Adherence was assessed during 51 weeks in 26 of the 29 participants enrolled in the MEMS substudy for whom data were available. As shown in Table 1 , the 26 participants received tenofovir disoproxil fumarate/emtricitabine, plus an NNRTI in 21 cases and a boosted PI in 5 cases. Their baseline data were comparable to those of the entire group. Bottle openings were consistent with the 4/7 regimen in 90% of patients each week (89.9%-96.9%) (Figure 3b ). For each of the 26 patients, the median number of weeks with bottle opening exactly 4 days a week was 44/51 weeks; bottle opening was ,4 days in 5/51 weeks and .4 days in 2/51 weeks.
The patients expressed a high degree of satisfaction with the 4/7 strategy: 78.6% were fully satisfied at W48, versus 57.5% at D0 (on the 7/7 strategy); 9.1% were not satisfied (versus 19.3% at D0), with an OR of 5.2 (95% CI 2.0-13.7, P , 0.001). Three of the eight PROQOL-HIV dimensions improved over time (stigma: !8.8+3.6, P " 0.016; health concerns: !4.5+1.9, P " 0.019; and treatment impact: !3.2+0.9, P " 0.001).
Discussion
The 96% success rate observed here at W48 with a 4-days-a-week antiretroviral regimen compares favourably with other tripleagent maintenance strategies and simplified regimens (PI/r monotherapy or dual combinations), for which 1 year success rates ranged from 65% to 88%. 7, [15] [16] [17] [18] [19] The amount of proviral DNA, a surrogate size marker of the HIV-1 reservoir, which reflects the potential for viral rebound during and after treatment interruption, [20] [21] [22] was remarkably stable from D0 to W48. Similarly, no increase in markers of inflammation was observed during the study. These data support the hypothesis of absence of immune degradation or inflammatory activation under reduced maintenance therapy: continued CD4 elevation and improvement of the CD4/CD8 ratio, stability of the viral reservoir attested by absence of HIV-DNA increase, absence of elevation of inflammatory markers and even a tendency to a decrease in monocyte activation markers (CD14s), indicating a low probability of viral reactivation. Although genital compartment HIV-1 shedding was not measured, it is unlikely that there was any change in the seminal HIV-1 VL, given that no change was seen in HIV DNA level over the course of the trial.
Adherence questionnaires, together with low residual drug levels during the 3 day off-treatment period and the results of the MEMS-cap substudy, showed good adherence to the 4/7 strategy.
Short-cycle structured intermittent maintenance therapy was first evaluated in a 7 days on/7 days off regimen as proof of Figure 2 . Probability of therapeutic success (Kaplan-Meier). Data for one patient were excluded at week 12 because of study treatment discontinuation due to pregnancy.
de Truchis et al. HIV short-cycle maintenance therapy JAC concept, 8 and then in a 5 days on/2 days off strategy in small or uncontrolled studies, with relative success. 10, 23, 24 Recently, the multicentre, randomized BREATHER study, involving 199 young patients, demonstrated the non-inferiority of 5-days-aweek efavirenz-based therapy compared with daily therapy (virological failure: 6% versus 7%, difference: #1.2%, 90% CI #7.3% to -4.9%). 9 We report a high level of efficacy with our 4 days on/3 days off NNRTI-and PI-based triple-agent maintenance strategy in this multicentre prospective trial. The very low rate of virological rebound observed here is compatible with the results of treatment discontinuation studies that indicate a latency period of 5-8 days before the resumption of viral replication. 25, 26 This latency may be related to the long half-life of NNRTI, as confirmed here by noteworthy residual plasma concentrations (.IC 90 ) of efavirenz, rilpivirine and etravirine on the third day of treatment interruption. In three ART interruption studies, viral escape occurred after at least 5-7 days after stopping NNRTI. [27] [28] [29] However, this pharmacological explanation does not seem suitable for PI-based therapy in which residual concentrations after ART interruption are low, with a shorter plasmatic half-life than NNRTI. In this case, the latency before VL rebound after treatment interruption could partially be explained by the long intracellular half-life of PIs, owing to their high binding affinity, especially for darunavir which has a dissociative half-life .240 h. 30 Owing to the high efficiency of the 4/7 day regimen, the costbenefit evaluation is obviously positive, with a 40% reduction in the cost of antiviral drugs, i.e. a saving of about e4800 per patient-year Changes from baseline in biological parameters at W48 were compared using the non-parametric Wilcoxon paired test. Missing values at W48 were replaced using the last observation carried forward (LOCF) method. To assess quality of life in the PROQOL-HIV questionnaire, each item was scored on a 0-100 scale and the multiple imputation method was used to estimate missing values. Ten datasets in which missing data were imputed from each patient's other covariables, including all items in the PROQOL-HIV questionnaire, age, sex, transmission group, origin, prior AIDS events, the type of treatment (2 INSTI ! PI/r versus 2 INSTI ! NNRTI), time of suppressed HIV viraemia ,50 copies/mL and duration of ART. Changes from baseline at W48 in quality of life dimensions were compared using Student's t-test. Analyses were run on each of the 10 datasets, including the imputed values, and the results were combined with Rubin's rules.
de Truchis et al. Figure 3 . Adherence to the study strategy. (a) Assessment of treatment adherence with a self-reported questionnaire based on last-week recall at each visit. The adherence rate for each participant was estimated as the number of pills consumed divided by the number of pills that should theoretically have been consumed and was classified as low (,80%), medium (80%-95%), high (95%-100%) or higher than expected (.100%).
(b) Proportion of days on which MEMS-caps were opened according to the chosen weekly schedule (Monday-Thursday or Tuesday-Friday). The proportion was calculated as the number of days that the MEMS-cap was opened at least once divided by the total number of days under study.
HIV short-cycle maintenance therapy JAC of maintenance therapy. The '3 day therapeutic weekend' was greatly appreciated by the participants, demonstrated by a high level of satisfaction with the study regimen, being easy to remember and allowing them a standard lifestyle (e.g. ease of visiting friends or family on weekends without being disturbed by treatment intake). Evaluation of clinical or biological benefit is limited in our study because patients were maintained under their previous successful and well-tolerated ART combination and the lack of a control group. In addition to a cost reduction, the overall 40% reduction in drug exposure could reduce long-term toxicity. Other maintenance strategies currently under evaluation, such as the use of long-acting agents in patients with controlled VL, will not present the same advantages.
In conclusion, in a population of patients on effective long-term NNRTI-or boosted-PI-based ART, short-cycle maintenance therapy with 4 days on and 3 days off treatment was safe, well accepted and virologically effective for 1 year. A longer, randomized study with other ART combinations, including integrase inhibitors, is warranted to confirm the benefits and effectiveness of a 4-days-a-week maintenance strategy.
